Negative / Null Result ReportOpen accessMedicine· cited by 42

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort

Anwaar Saeed; Robin Park; Harsh B. Pathak; Ayah N. Al-Bzour; Junqiang Dai; Milind A. Phadnis; Raed Moh’d Taiseer Al-Rajabi; Anup Kasi · 2024 · Nature Communications

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%. In post-hoc analysis of patients with RAS wild type tumors, ORR was 50% and median PFS and OS were 6.3 and 21.5 months respectively. Explo

Abstract by Anwaar Saeed; Robin Park; Harsh B. Pathak; Ayah N. Al-Bzour; Junqiang Dai; Milind A. Phadnis; Raed Moh’d Taiseer Al-Rajabi; Anup Kasi, Nature Communications (2024) — licensed CC BY 4.0.

Read the full paper (open access)